RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
+15.75%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$3.94B
AUM Growth
+$3.94B
(+8.1%)
Cap. Flow
+$90.3M
Cap. Flow
% of AUM
2.29%
Top 10 Holdings %
Top 10 Hldgs %
26.69%
Holding
163
New
20
Increased
50
Reduced
30
Closed
15
Top Buys
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$50.5M |
| 2 |
INZY
Inozyme Pharma
INZY
|
$23.1M |
| 3 |
Kymera Therapeutics
KYMR
|
$22.9M |
| 4 |
Acadia Pharmaceuticals
ACAD
|
$21.4M |
| 5 |
Humana
HUM
|
$21.3M |
Top Sells
| 1 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
$41.5M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
$31.6M |
| 3 |
Cigna
CI
|
$30.2M |
| 4 |
Amgen
AMGN
|
$29.7M |
| 5 |
Allogene Therapeutics
ALLO
|
$18.9M |
Sector Composition
| 1 | Healthcare | 90.05% |
| 2 | Consumer Staples | 1.43% |
| 3 | Consumer Discretionary | 0.93% |
| 4 | Industrials | 0.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Biogen
BIIB
$20.8B
| $48.9M | 1.24% |
172,500
-7,500
| -4% | -$2.13M |
|
|
SGEN
27
DELISTED
Seagen Inc. Common Stock
SGEN
| $48.9M | 1.24% |
250,000
| – | – |
|
28
Sarepta Therapeutics
SRPT
$2B
| $48.5M | 1.23% |
345,500
| – | – |
|
29
Ultragenyx Pharmaceutical
RARE
$3.06B
| $47.4M | 1.2% |
576,841
-70,000
| -11% | -$5.75M |
|
30
Align Technology
ALGN
$9.58B
| $46.8M | 1.19% |
143,000
| – | – |
|
31
Edwards Lifesciences
EW
$47.3B
| $46.5M | 1.18% |
582,000
| – | – |
|
32
Encompass Health
EHC
$12.4B
| $45.4M | 1.15% |
698,000
-134,500
| -16% | -$8.74M |
|
33
Teleflex
TFX
$5.54B
| $44.3M | 1.12% |
130,000
| – | – |
|
34
Exact Sciences
EXAS
$9.12B
| $43.2M | 1.1% |
424,000
| – | – |
|
35
Boston Scientific
BSX
$158B
| $42M | 1.07% |
1,100,000
| – | – |
|
36
Ascendis Pharma
ASND
$12B
| $36M | 0.91% |
233,500
+20,000
| +9% | +$3.09M |
|
37
Mersana Therapeutics
MRSN
$35.3M
| $35.1M | 0.89% |
1,885,428
+7,000
| +0.4% | +$130K |
|
38
Penumbra
PEN
$10.5B
| $30.9M | 0.78% |
159,000
-48,000
| -23% | -$9.33M |
|
39
Adaptive Biotechnologies
ADPT
$1.94B
| $30.9M | 0.78% |
635,000
+60,000
| +10% | +$2.92M |
|
40
Coherus Oncology, Inc. Common Stock
CHRS
$144M
| $30.5M | 0.78% |
1,665,449
-359,826
| -18% | -$6.6M |
|
41
Inspire Medical Systems
INSP
$2.51B
| $30.5M | 0.77% |
236,000
-29,000
| -11% | -$3.74M |
|
|
EPZM
42
DELISTED
Epizyme, Inc
EPZM
| $30.4M | 0.77% |
2,551,659
+447,575
| +21% | +$5.34M |
|
43
Madrigal Pharmaceuticals
MDGL
$9.53B
| $30.2M | 0.77% |
254,268
| – | – |
|
|
CVET
44
DELISTED
Covetrus, Inc. Common Stock
CVET
| $29.9M | 0.76% |
1,225,000
+387,500
| +46% | +$9.46M |
|
45
Incyte
INCY
$16.9B
| $26.9M | 0.68% |
300,000
+50,000
| +20% | +$4.49M |
|
46
Ardelyx
ARDX
$1.56B
| $26.7M | 0.68% |
5,076,867
+61,758
| +1% | +$324K |
|
47
BioMarin Pharmaceuticals
BMRN
$11.3B
| $26.6M | 0.68% |
350,000
-37,500
| -10% | -$2.85M |
|
48
Immunovant
IMVT
$2.9B
| $26.1M | 0.66% |
742,449
+290,130
| +64% | +$10.2M |
|
|
ALXN
49
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $25.7M | 0.65% |
225,000
+41,500
| +23% | +$4.75M |
|
50
Health Catalyst
HCAT
$227M
| $25.7M | 0.65% |
703,000
+278,000
| +65% | +$10.2M |
|